MedTrace Logo

Testicular Sperm Aspiration (TESA) vs. Microfluidic Sperm Separation (MSS)

NCT05866484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 280

Last updated 2024-07-12

No results posted yet for this study

Summary

Normal embryonic development relies on the correct transmission of genetic information, and sperm DNA plays a crucial part in this process. Causes of poor sperm DNA integrity include unhealthy lifestyles such as smoking and exposure to gonadotoxins, as well as, obesity, varicoceles, infections, advanced paternal age and systemic disorders. An increase in DNA fragmentation in sperm has been linked to lower fertilisation rate, poorer quality embryos, lower pregnancy rate, and high miscarriages rate.

The best way for sperm selection and processing in assisted reproductive technologies (ART) should be noninvasive and cost-effective. It should also make it possible to identify high-quality spermatozoa and produce more favorable results in terms of pregnancy and live birth rates.7 Meanwhile, the microfluidic sperm separation technology is a less expensive and less invasive alternative. This method allows for the selection of motile sperm that have a normal morphology, low levels of reactive oxygen species (ROS), and low DFI

Conditions

  • Infertility, Male
  • Azoospermia
  • Reproductive Disorder

Sponsors & Collaborators

  • Clinique Ovo

    lead INDUSTRY

Principal Investigators

  • Armand Zini, MD · Clinique Ovo

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2024-03-30
Completion
2024-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05866484 on ClinicalTrials.gov